The incidence and risk factors of resistant E. coli infections after prostate biopsy under fluoroquinolone prophylaxis: a single-centre experience with 2215 patients
- 3 July 2016
- journal article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 28 (4) , 284-288
Abstract
We evaluated the incidence and risk factors of resistant Escherichia coli infections after the prostate biopsy under flouroquinolone prophylaxis. From January 2003 to December 2012, we retrospectively evaluated the records of 2215 patients. The risk factors were described for infective complications and resistant E. coli in positive cultures was calculated. Of 2215 patients, 153 had positive urine cultures, such as 129 (84·3%) E. coli, 8 (5·2%) Enterococcus spp., 6 (3·9%) Enterobacter spp., 5 (3·2%) Pseudomonas spp., 3 (1·9%) MRCNS, and 2 (1·3%) Klebsiella spp. Of the positive urine cultures which yielded E. coli, 99 (76·7%) were evaluated for fluoroquinolone resistance. Of those, 83 (83·8%) were fluoroquinolone-resistant and composed of 51 (61·4%) extended-spectrum beta-lactamase (ESBL)-positive. Fluoroquinolone-resistant E. coli ratios were 73·4 and 95·9% before 2008 and after 2008, respectively (P = 0·002). The most sensitive antibiotics for fluoroquinolone-resistant E. coli strains were imipenem (100%), amikacin (84%) and cefoperazone (83%). The use of quinolones in the last 6 months and a history of hospitalization in the last 30 days were found to be significant risk factors. We found that resistant E. coli strains might be a common microorganism in patients with this kind of complication. The risk factors for development of infection with these resistant strains were history of the use of fluoroquinolones and hospitalization.Keywords
This publication has 19 references indexed in Scilit:
- Prevalence and pathogenesis of extended-spectrum beta-lactamase producing Escherichia coli causing urinary tract infection in hospitalized patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogensEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- Risk Factors for Acute Prostatitis after Transrectal Biopsy of the ProstateKorean Journal of Urology, 2010
- Incidence of Acute Prostatitis Caused by Extended-spectrum β-Lactamase-producing Escherichia coli After Transrectal Prostate BiopsyUrology, 2009
- Prevalence and Risk Factors for Selection of Quinolone-Resistant Escherichia coli Strains in Fecal Flora of Patients Receiving Quinolone TherapyAntimicrobial Agents and Chemotherapy, 2009
- The Incidence of Fluoroquinolone Resistant Infections After Prostate Biopsy—Are Fluoroquinolones Still Effective Prophylaxis?Journal of Urology, 2008
- Epidemiology and risk factors for extended-spectrum β-lactamase-producing organisms: A case control study at a tertiary care center in LebanonAmerican Journal of Infection Control, 2005
- Incidence of Urinary Tract Infection Following Transrectal Ultrasound Guided Prostate Biopsy at a Tertiary-Care Medical Center in LebanonInfection Control, 2004
- Extended-Spectrum -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on OutcomesClinical Infectious Diseases, 2001
- BACTEREMIA AND BACTERIURIA AFTER TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSYJournal of Urology, 2000